Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

Tar­get­ing over­ac­tive white blood cells known as eosinophils has be­come a hot drug tar­get with mul­ti­ple ap­provals in re­cent years. One com­pa­ny with big plat­form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER